Chronic Disease
Our work in Chronic Disease
-
Response to Sen. Cassidy’s Request for Information on Improving Americans’ Access to Gene Therapies
Schaeffer experts submitted a comment letter responding to a request for information from stakeholders about improving access to cell and gene therapies for ultra-rare diseases.
Categorized in -
Assessment of the U.S. Food and Drug Administration’s Risk Evaluation and Mitigation Strategy (REMS) for Prasugrel (EFFIENT): A Narrative Review
The prasugrel REMS consisted of passive educational materials whose adequacy was evaluated using highly limited, one-time, cross-sectional surveys. The study’s assessment adds to evidence suggesting the importance of improving the quality and impact of the FDA’s post-approval activities to maximize drug safety.
Categorized in -
Biden’s Hepatitis C Initiative Needs Help from the Private Market
Instead of this massive nationalized program, the White House could make four administrative changes that would jump-start private-sector solutions in each state.
Categorized in -
Seminar Series – Anup Malani
Anup Malani is a legal scholar and economist. He is the Lee & Brena Freeman Professor at the University of Chicago Law School and a Research Associate at the National Bureau of Economic Research.
-
Want Lower Obesity Drug Costs? Medicare Holds the Key
Medicare coverage will catalyze market competition
Categorized in -
Adherence and Persistence of HIV Pre-Exposure Prophylaxis Use in the United States
Adherence to daily PrEP is high among commercially insured individuals but the majority still discontinue in the first year.
Categorized in -
Comments in Response to a CBO Call for New Research on Obesity
While there are significant data and methodological challenges to be overcome, there are better alternatives to simplistically extrapolating from the real-world data on AOM use that is currently available.
Categorized in -
Seminar Series – Adriana Corredor-Waldron
Adriana Corredor-Waldron is an economist studying health disparities and mental health in the United States. She is an Assistant Professor of Economics at North Carolina State University.
-
Seminar Series – Lorens Helmchen
Lorens A. Helmchen, PhD, is an Associate Professor of Health Policy and Management in the Milken Institute School of Public Health at The George Washington University.
-
Changes in HIV Pre-exposure Prophylaxis (PrEP) Coverage at State and County Level During the COVID-19 Pandemic in the United States
Weekly PrEP use declined during the COVID-19 pandemic in 2020, with only 1 in 12 persons at high risk for HIV taking PrEP at least once a week by November 2020 in the U.S.
Categorized in